MX2013003558A - Sales de oxalato cristalinas de un compuesto diamida. - Google Patents

Sales de oxalato cristalinas de un compuesto diamida.

Info

Publication number
MX2013003558A
MX2013003558A MX2013003558A MX2013003558A MX2013003558A MX 2013003558 A MX2013003558 A MX 2013003558A MX 2013003558 A MX2013003558 A MX 2013003558A MX 2013003558 A MX2013003558 A MX 2013003558A MX 2013003558 A MX2013003558 A MX 2013003558A
Authority
MX
Mexico
Prior art keywords
crystalline oxalate
oxalate salts
diamide compound
crystalline
oxalate salt
Prior art date
Application number
MX2013003558A
Other languages
English (en)
Spanish (es)
Inventor
Miroslav Rapta
Robert Chao
Venkat Thalladi
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of MX2013003558A publication Critical patent/MX2013003558A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2013003558A 2010-09-30 2011-09-29 Sales de oxalato cristalinas de un compuesto diamida. MX2013003558A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38814810P 2010-09-30 2010-09-30
PCT/US2011/053997 WO2012044825A1 (en) 2010-09-30 2011-09-29 Crystalline oxalate salts of a diamide compound

Publications (1)

Publication Number Publication Date
MX2013003558A true MX2013003558A (es) 2013-05-01

Family

ID=44903347

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013003558A MX2013003558A (es) 2010-09-30 2011-09-29 Sales de oxalato cristalinas de un compuesto diamida.

Country Status (19)

Country Link
US (1) US8697724B2 (enExample)
EP (1) EP2621917A1 (enExample)
JP (2) JP2013538857A (enExample)
KR (1) KR20130139919A (enExample)
CN (1) CN103140485B (enExample)
AR (1) AR083115A1 (enExample)
AU (1) AU2011308770B2 (enExample)
BR (1) BR112013007062A2 (enExample)
CA (1) CA2810896A1 (enExample)
CL (1) CL2013000870A1 (enExample)
CO (1) CO6700846A2 (enExample)
EA (1) EA022018B1 (enExample)
IL (1) IL224985A (enExample)
MX (1) MX2013003558A (enExample)
NZ (1) NZ608721A (enExample)
PH (1) PH12013500567A1 (enExample)
SG (1) SG188390A1 (enExample)
TW (1) TW201217338A (enExample)
WO (1) WO2012044825A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20110083U1 (it) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire Piastra per la costruzione di carrelli per aeroplani
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
BR112015013628A2 (pt) 2012-12-18 2017-07-11 Almirall Sa derivados de carbamato de ciclo-hexila e quinuclidinila tendo atividades agonista adrenérgica de beta2 e antagonista muscarínica de m3
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
CN104030933A (zh) * 2014-05-16 2014-09-10 烟台恒迪克能源科技有限公司 一种β-异烷醇基氨基戊酸环己胺的合成方法
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
CN117924216A (zh) * 2024-01-12 2024-04-26 王叔和生物医药(武汉)有限公司 一种1-哌啶丙酸的合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
CO5310534A1 (es) 2000-08-05 2003-08-29 Glaxo Group Ltd Nuevos derivados de androstano anti-inflamatorios
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
JP4767842B2 (ja) * 2003-04-01 2011-09-07 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有するジアリールメチル化合物および関連化合物
WO2005080375A1 (en) 2004-02-13 2005-09-01 Theravance, Inc. Crystalline form of a biphenyl compound
WO2006023460A2 (en) * 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
TWI374883B (en) 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound
GB0602778D0 (en) * 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
TW200811104A (en) 2006-04-25 2008-03-01 Theravance Inc Crystalline forms of a dimethylphenyl compound
CN103936716B (zh) * 2009-04-23 2016-09-07 施万呼吸有限责任公司 具蕈毒碱受体拮抗剂和β2肾上腺素受体激动剂活性的二酰胺化合物

Also Published As

Publication number Publication date
EP2621917A1 (en) 2013-08-07
IL224985A (en) 2015-08-31
EA201390481A1 (ru) 2013-08-30
AR083115A1 (es) 2013-01-30
JP2015155470A (ja) 2015-08-27
CA2810896A1 (en) 2012-04-05
NZ608721A (en) 2015-03-27
JP2013538857A (ja) 2013-10-17
US20120083478A1 (en) 2012-04-05
AU2011308770A1 (en) 2013-03-28
BR112013007062A2 (pt) 2016-06-14
EA022018B1 (ru) 2015-10-30
CN103140485B (zh) 2014-10-22
CL2013000870A1 (es) 2013-07-12
SG188390A1 (en) 2013-04-30
CN103140485A (zh) 2013-06-05
CO6700846A2 (es) 2013-06-28
WO2012044825A1 (en) 2012-04-05
KR20130139919A (ko) 2013-12-23
AU2011308770B2 (en) 2015-03-05
PH12013500567A1 (en) 2013-05-06
TW201217338A (en) 2012-05-01
US8697724B2 (en) 2014-04-15

Similar Documents

Publication Publication Date Title
MX2013003558A (es) Sales de oxalato cristalinas de un compuesto diamida.
IL257390B (en) Salts of 1-((4-methoxymethyl)-4-(((s2,r1)-2-phenyl-cyclopropylamine)methyl)piperidine-1-yl)methyl)-cyclobutane-carboxylic acid as lsd1 inhibitors
WO2007127297A3 (en) Crystalline forms of a dimethylphenyl compound
NZ602665A (en) Solid forms of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihyderoxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide
MX2012000682A (es) Formas de bases libres cristalinas de un compuesto de bifenilo.
TW200714586A (en) Crystalline forms of a biphenyl compound
WO2014188453A3 (en) Novel process for the preparation of 2-[4-(2-{4-[1-(2-ethoxyethyl)-1h-benzimidazol-2-yl]-1-piperidinyl}ethyl) phenyl]-2-methylpropanoic acid
EA201491079A1 (ru) Арил дигидропиридиноновые и пиперидиноновые ингибиторы mgat2
UA108378C2 (uk) Спосіб одержання плеуромутилінів
WO2012138147A3 (en) 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid crystalline form and the producing method thereof
WO2011110876A8 (en) Novel salts for the manufacture of pharmaceutical compositions
HK1206021A1 (en) Novel ring-substituted n-pyridinyl amides as kinase inhibitors
BR102013003576B8 (pt) Método para produzir n-ciano-s-metil-s-[1-(6-tri-flúormetil-3-piridinil)etil]sulfilimina
CO6710915A2 (es) Composiciones farmacéuticas que contienen un inhibidor de dgat1 ácido 4-(4-(5-6(- trifluorometil-piridin -3- ilamino)-piridin- 2-il)fenil)cicloheiyl)-acético o sales del mismo
PH12012501438A1 (en) Method for preparing tetrazole methanesulfonic acid salts, and novel compound used in same
MX2012001411A (es) Proceso para la preparacion de derivados de acido 1-(2-halobifenil-4-il)-ciclopropanocarboxilico.
IN2015DN02424A (enExample)
MX2011011849A (es) Proceso para la preparacion de un compuesto util como inhibidor de tafia.
UA110822C2 (uk) Піперидинілмонокарбонові кислоти як агоністи s1p1-рецепторів
EA201200726A1 (ru) Способ синтеза, кристаллическая форма 4-{3-[цис-гексагидроциклопента[c]пиррол-2(1н)ил]пропокси}бензамид гидрохлорида и фармацевтические композиции, которые ее содержат
CY1112979T1 (el) Διαδικασια για την παρασκευη της ενωσης (s)-1-αλκυλ-2',6'-πιπεκολοξυλιδιδιου
MX2010003184A (es) Nuevo procedimiento de sinstesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable.
MX2015010561A (es) Sintesis asimetrica de una pirrolidin-2-carboxamida sustituida.
HK1186729A (en) Crystalline oxalate salts of a diamide compound
MX2010002300A (es) Polimorfos de sal sodica del acido (3-(((4-terc-butil-bencil)-(pir idin-3-sulfonil)-amino)-metil)-fenoxi)-acetico o un hidrato de los mismos y procedimientos para fabricar los mismos.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal